John Varga

32.8k total citations · 6 hit papers
279 papers, 20.2k citations indexed

About

John Varga is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John Varga has authored 279 papers receiving a total of 20.2k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Pathology and Forensic Medicine, 100 papers in Molecular Biology and 76 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Varga's work include Systemic Sclerosis and Related Diseases (164 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (63 papers) and Connective Tissue Growth Factor Research (37 papers). John Varga is often cited by papers focused on Systemic Sclerosis and Related Diseases (164 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (63 papers) and Connective Tissue Growth Factor Research (37 papers). John Varga collaborates with scholars based in United States, United Kingdom and France. John Varga's co-authors include Swati Bhattacharyya, David Abraham, Sergio A. Jiménez, Yasuji Mori, Maria Trojanowska, Asish K. Ghosh, Jun Wei, Weihua Yuan, Monique Hinchcliff and Vallerie V. McLaughlin and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and Circulation.

In The Last Decade

John Varga

273 papers receiving 19.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

2009 1.8k citations Vallerie V. McLaughlin, Stephen L. Archer et al. profile →
Recent Developments in Myofibroblast Biology

2012 989 citations Boris Hinz, Sem H. Phan et al. American Journal Of Pathology profile →
Systemic sclerosis: a prototypic multisystem fibrotic disorder

2007 897 citations John Varga et al. profile →
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

2009 844 citations Vallerie V. McLaughlin, Stephen L. Archer et al. Circulation profile →
Systemic sclerosis

2015 575 citations Robert W. Simms, Christopher P. Denton et al. profile →
Transforming growth factor β (TGFβ) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts

1987 529 citations John Varga, Sergio A. Jiménez et al. profile →

Peers

Countries citing papers authored by John Varga

Since Specialization

Citations

This map shows the geographic impact of John Varga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Varga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Varga more than expected).

Fields of papers citing papers by John Varga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Varga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Varga. The network helps show where John Varga may publish in the future.

Co-authorship network of co-authors of John Varga

This figure shows the co-authorship network connecting the top 25 collaborators of John Varga. A scholar is included among the top collaborators of John Varga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Varga. John Varga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	General Attitudes towards Artificial Intelligence Scale (GAAIS): Hungarian adaptation and links to personality traits 2025 ·Frontiers in Psychology ·(unknown), Szabolcs Bandi, (unknown), (unknown), John Varga, (unknown), Róbert Herold, János Kállai	0
2	Elevated Circulating Levels of Gut Microbe-Derived Trimethylamine N-Oxide Are Associated with Systemic Sclerosis 2024 ·Journal of Clinical Medicine ·Karen J. Ho, Lutfiyya N. Muhammad, (unknown), Xinmin S. Li, Mary Carns, Kathleen Aren, (unknown), Priyanka Verma, Stanley L. Hazen, John Varga	1
3	Extracellular Matrix–Derived Damage-Associated Molecular Patterns (DAMP): Implications in Systemic Sclerosis and Fibrosis 2023 ·Journal of Investigative Dermatology ·Swarna Bale, Priyanka Verma, John Varga, Swati Bhattacharyya	21
4	Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial 2022 ·Arthritis & Rheumatology ·Dinesh Khanna, Paul H. Caldron, Richard W. Martin, Suzanne Kafaja, Robert Spiera, (unknown), Ankoor R. Shah, Vivien Hsu, John Ervin, Robert W. Simms, Robyn T. Domsic, Virginia Steen, Laura K. Hummers, Chris T. Derk, Maureen D. Mayes, Soumya Chatterjee, John Varga, Steven Kesten, John K. Fraser, Daniel E. Furst	20
5	Senescence Signature in Skin Biopsies From Systemic Sclerosis Patients Treated With Senolytic Therapy: Potential Predictor of Clinical Response? 2019 ·Arthritis & Rheumatology ·Viktor Martyanov, Michael L. Whitfield, John Varga	38
6	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease 2019 ·American Journal of Respiratory and Critical Care Medicine ·Dinesh Khanna, Donald P. Tashkin, Christopher P. Denton, Elisabetta Renzoni, Sujal R. Desai, John Varga	128
7	Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease 2017 ·PLoS ONE ·Viktor Martyanov, Grace Hyun J. Kim, Wendy Hayes, Shuyan Du, Bishu Ganguly, Oumar Sy, (unknown), Galina S. Bogatkevich, Gary L. Schieven, Elena Schiopu, Roberta Gonçalves Marangoni, Jonathan Goldin, Michael L. Whitfield, John Varga	58
8	Lrp5/β-Catenin Signaling Controls Lung Macrophage Differentiation and Inhibits Resolution of Fibrosis 2016 ·American Journal of Respiratory Cell and Molecular Biology ·Joseph A. Sennello, Alexander V. Misharin, Annette S. Flozak, Sergejs Berdnikovs, Paul Cheresh, John Varga, David W. Kamp, G. R. Scott Budinger, Cara J. Gottardi, Anna P. Lam	45
9	Fibronectin ^EDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor Signaling 2014 ·Science Translational Medicine ·Swati Bhattacharyya, Zenshiro Tamaki, Wenxia Wang, Monique Hinchcliff, Paul Hoover, Spiro Getsios, Eric S. White, John Varga	178
10	Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. 2012 ·Clinical and Experimental Rheumatology ·Monique Hinchcliff, Chintan Desai, John Varga, Sanjiv J. Shah	71
11	Recent Developments in Myofibroblast Biology breakdown → 2012 ·American Journal Of Pathology ·Boris Hinz, Sem H. Phan, Victor J. Thannickal, Marco Prunotto, Alexis Desmoulière, John Varga, Olivier De Wever, Marc Mareel, Giulio Gabbiani	989
12	Toll-Like Receptor 4 Signaling Augments Transforming Growth Factor-β Responses 2012 ·American Journal Of Pathology ·Swati Bhattacharyya, Kathleen Kelley, Denisa S. Melichian, Zenshiro Tamaki, Feng Fang, Yunyun Su, (unknown), Richard M. Pope, G. R. Scott Budinger, Gökhan M. Mutlu, Robert Lafyatis, Timothy Radstake, Carol Feghali‐Bostwick, John Varga	209
13	Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1 2009 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Guofei Zhou, Laura A. Dada, Minghua Wu, Aileen Kelly, Humberto E. Trejo Bittar, Qiyuan Zhou, John Varga, Jacob I. Sznajder	193
14	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension breakdown → 2009 ·Circulation ·Vallerie V. McLaughlin, Stephen L. Archer, David B. Badesch, Robyn J. Barst, Harrison W. Farber, Jonathan R. Lindner, Michael A. Mathier, Michael D. McGoon, Myung H. Park, Robert S. Rosenson, Lewis J. Rubin, Victor F. Tapson, John Varga	844
15	Fibrosis Research 2005 ·Humana Press eBooks ·John Varga, David A. Brenner, Sem H. Phan, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	15
16	Fibrosis research : methods and protocols 2005 ·Humana Press eBooks ·John Varga, David A. Brenner, Sem H. Phan	23
17	Transcriptional coactivators p300/CBP and Type I collagen gene expression 2003 ·Current Science ·Asish K. Ghosh, John Varga	5
18	Lipoxin A4 Inhibits IL-1β-Induced IL-6, IL-8, and Matrix Metalloproteinase-3 Production in Human Synovial Fibroblasts and Enhances Synthesis of Tissue Inhibitors of Metalloproteinases 2000 ·The Journal of Immunology ·Snežna Sodin‐Šemrl, Brunella Taddeo, (unknown), John Varga, Stefano Fiore	184
19	Lung involvement in systemic sclerosis (scleroderma): Relation to classification based on extent of skin involvement or autoantibody status 1996 ·Pneumologie ·(unknown), John Varga, Emily F. Conant, Paul W. Spirn, Sergio A. Jiménez, Irving Fish	2
20	Augmentation mammoplasty and scleroderma. Is there an association? 1990 ·PubMed ·John Varga, Sergio A. Jiménez	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact